A Novel Therapeutic Strategy Targeting the Mesenchymal Phenotype of Malignant Pleural Mesothelioma by Suppressing LSD1
A Novel Therapeutic Strategy Targeting the Mesenchymal Phenotype of Malignant Pleural Mesothelioma by Suppressing LSD1
复制标题
通过抑制 LSD1 靶向恶性胸膜间皮瘤间质表型的新治疗策略
DOI:
10.1158/1541-7786.mcr-21-0230
复制
发表时间:
2021
影响因子:
5.2
通讯作者:
Takahashi K
中科院分区:
文献类型:
--
作者:
Wirawan Aditya;Tajima Ken;Takahashi Fumiyuki;Mitsuishi Yoichiro;Winardi Wira;Hidayat Moulid;Hayakawa Daisuke;Matsumoto Naohisa;Izumi Kenta;Asao Tetsuhiko;Ko Ryo;Shimada Naoko;Takamochi Kazuya;Suzuki Kenji;Abe Masaaki;Hino Okio;Sekido Yoshitaka;Takahashi K
Malignant pleural mesothelioma (MPM) is a highly aggressive tumor that has a low overall survival; however, no significant treatment advances have been made in the past 15 years. Large-scale molecular studies have identified a poor prognostic subset of MPM linked to the epithelial–mesenchymal transition (EMT) that may contribute toward resistance to chemotherapy, suggesting that EMT could be targeted to treat patients with MPM. Previously, we reported that histone modifiers regulating EMT could be therapeutic targets; therefore, in this study, we investigated whether targeting lysine-specific demethylase 1 (LSD1/KDM1), a histone-modifying enzyme responsible for demethylating histone H3 lysine 4 and lysine 9, could represent a novel therapeutic strategy for MPM. We suppressed LSD1 and investigated the EMT phenotype using EMT marker expression and wound-healing assay; and chemosensitivity using apoptosis assay. We found that suppressing LSD1 induces an epithelial phenotype in sarcomatoid MPM cells, while attenuating the mesenchymal phenotype sensitized MPM cells to cisplatin-induced apoptosis. Subsequent genome-wide identification, comprehensive microarray analysis, and Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq) to assess genome-wide changes in chromatin accessibility suggested that LSD1 directly regulates milk fat globulin protein E8 (MFGE8), an integrin ligand that is involved in the FAK pathway. Furthermore, we found that LSD1 regulates the mesenchymal phenotype and apoptosis by activating the FAK–AKT–GSK3β pathway via a positive feedback loop involving MFGE8 and Snail expression, thereby leading to cisplatin resistance.ImplicationsThis study suggests that LSD1 regulates the mesenchymal phenotype and apoptosis, and that LSD1 inhibitors could be combined with the cisplatin as a novel therapy for patients with MPM.
登录
查看更多内容
影响因子:
11.2
作者:
Jinushi, Masahisa;Nakazaki, Yukoh;Dranoff, Glenn
通讯作者:
Dranoff, Glenn
影响因子:
11.2
作者:
Yang C;Hayashida T;Forster N;Li C;Shen D;Maheswaran S;Chen L;Anderson KS;Ellisen LW;Sgroi D;Schmidt EV
通讯作者:
Schmidt EV
DOI:
--
发表时间:
2006
期刊:
影响因子:
--
作者:
Usami N;Fukui T;Kondo M;Taniguchi T;Yokoi K;Shimokata K;Hida T;Sekido Y
通讯作者:
Sekido Y
DOI:
--
发表时间:
--
期刊:
影响因子:
--
作者:
通讯作者:
--
影响因子:
8.8
作者:
Luo, Huacheng;Shenoy, Anitha K.;Lu, Jianrong
通讯作者:
Lu, Jianrong